Clinical Observation of Recombinant Human Growth Hormone Injection Assisted IVF-ET in the Treatment of PCOS
Clinical Observation of Recombinant Human Growth Hormone Injection Assisted IVF-ET in the Treatment of PCOS
Observe validity of Recombinant Human Growth Hormone Injection assisted in IVF-ET (in vitro
 fertilization and embryo transfer) treatment of PCOS (polycystic ovary syndrome) patients.
Inclusion Criteria:

 -  Age between 25 and 35 years old, married female and infertile.

 -  BMI≥25kg/m2.

 -  Diagnosed as PCOS.

 -  No obvious chronic organic diseases, such as liver, kidney, heart, lung, thyroid,
 adrenal disease.

 -  Subjects do not take part in other clinical trial study within 3 months.

 -  The subjects sign the informed consent form.

 Exclusion Criteria:

 -  BMI<25kg/m2.

 -  Hyperprolactinemia and congenital adrenal cortical hyperplasia.

 -  Diabetes, thyroid function hyperthyroidism, thyroid dysfunction, cushing's syndrome.

 -  Pelvic and peritoneal tumor and tumor secreting hyperandrogenism.

 -  Severe acute and chronic liver and kidney disease, such as liver cirrhosis, acute and
 chronic renal failure, hepatitis B virus activity.

 -  Liver and kidney dysfunction, AST/ALT is 2.5 times higher than the normal limit, the
 serum of creatinine is 2 times higher than the normal level.

 -  Diseases affecting outcome of IVF pregnancy, eg, hydrosalpinx, hysteromyoma>4 cm,
 adenomyosis, endometriosis, endometrial cyst of ovary, unilateral ovary, tuberculosis
 of reproductive system.

 -  Allergic to E. coli. expression product and its excipients.

 -  Being involved in other drug clinical researchers.

 -  The researchers consider who is not suitable for the group.